Last reviewed · How we verify
Ocrelizumab (CinnaGen, Iran)
Ocrelizumab (CinnaGen, Iran) is a CD20-targeting monoclonal antibody Biologic drug developed by Cinnagen. It is currently in Phase 3 development for Relapsing forms of multiple sclerosis, Primary progressive multiple sclerosis. Also known as: Xacrel®.
Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells.
Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells. Used for Relapsing forms of multiple sclerosis, Primary progressive multiple sclerosis.
At a glance
| Generic name | Ocrelizumab (CinnaGen, Iran) |
|---|---|
| Also known as | Xacrel® |
| Sponsor | Cinnagen |
| Drug class | CD20-targeting monoclonal antibody |
| Target | CD20 |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By binding to CD20, ocrelizumab induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, leading to the depletion of B cells. This mechanism is thought to be beneficial in treating autoimmune diseases such as multiple sclerosis and non-Hodgkin's lymphoma.
Approved indications
- Relapsing forms of multiple sclerosis
- Primary progressive multiple sclerosis
Common side effects
- Infusion-related reactions
- Infections
- Neurological disorders
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ocrelizumab (CinnaGen, Iran) CI brief — competitive landscape report
- Ocrelizumab (CinnaGen, Iran) updates RSS · CI watch RSS
- Cinnagen portfolio CI
Frequently asked questions about Ocrelizumab (CinnaGen, Iran)
What is Ocrelizumab (CinnaGen, Iran)?
How does Ocrelizumab (CinnaGen, Iran) work?
What is Ocrelizumab (CinnaGen, Iran) used for?
Who makes Ocrelizumab (CinnaGen, Iran)?
Is Ocrelizumab (CinnaGen, Iran) also known as anything else?
What drug class is Ocrelizumab (CinnaGen, Iran) in?
What development phase is Ocrelizumab (CinnaGen, Iran) in?
What are the side effects of Ocrelizumab (CinnaGen, Iran)?
What does Ocrelizumab (CinnaGen, Iran) target?
Related
- Drug class: All CD20-targeting monoclonal antibody drugs
- Target: All drugs targeting CD20
- Manufacturer: Cinnagen — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Relapsing forms of multiple sclerosis
- Indication: Drugs for Primary progressive multiple sclerosis
- Also known as: Xacrel®
- Compare: Ocrelizumab (CinnaGen, Iran) vs similar drugs
- Pricing: Ocrelizumab (CinnaGen, Iran) cost, discount & access